Catalist-listed metal-stamping firm CFM Holdings has on June 3 entered into a sale and purchase agreement (SPA) to acquire 51% of the issued share capital in  SING-SWE MM Biotechnology, a distributor of Covid-19 testing kits.

The acquisition is subject to shareholders’ approval, to be sought an extraordinary general meeting (EGM) to be held at a later date.

Under the SPA, CFM will acquire the shares for an aggregate consideration of $6.1 million, which will be satisfied through the issuance of up to 120 million new ordinary shares in CFM at an issue price of 5.1 cents per share.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook